Eramet


Top-line remains restrained, but EBITDA guidance was a surprise

29/10/26 -"Q3, while traditionally focused on sales (which remained restrained), was mostly about surprise 2026 EBITDA guidance – which implies that the H1 rebound should be sustained in H2. While the markets ..."

Pages
83
Language
English
Published on
29/10/26
You may also be interested by these reports :
29/10/26
Q3, while traditionally focused on sales (which remained restrained), was mostly about surprise 2026 EBITDA guidance – which implies that the H1 ...

28/10/26
SSAB’s Q326 results were broadly in line, with revenues up 11.6% YoY to SEK25.6bn and EBIT up 15.4% to SEK2.2bn, slightly ahead of expectations. ...

23/10/26
Even though Norsk’s Q3 results were strong in aggregate – led by Primary Metal – they missed street expectations. Also, all other divisions faced ...

23/10/26
Eyes are on Q3 earnings releases. Ours are on a trio of pair trades which seem to have legs. The first is a way to retain exposure to infra, a sector ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO